Based on the interim results of an ongoing phase 2 study of tovorafenib in pediatric, adolescent, and adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration (FIREFLY-1; NCT04775485) 18, tovorafenib monotherapy was approved in the United States for the treatment of patients aged ≥6 months who had relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, BRAF rearrangement, or BRAF V600 mutation 19. This evidence concerns the gene BRAF and low grade glioma.